Last reviewed · How we verify
Panhematin
At a glance
| Generic name | Panhematin |
|---|---|
| Also known as | Glucose |
| Sponsor | Rush University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | discontinued |
Approved indications
- Acute intermittent porphyria
Common side effects
Key clinical trials
- Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria (Phase 2)
- An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB) (Phase 4)
- Effect of Hemin on Heme-Oxygenase-1 Activity in Healthy Subjects (Phase 1)
- A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (Phase 2)
- Quantifying Menstrual Blood Loss: Validating the Methodology for Stable Iron Isotopes Dilution Against the Alkaline Hematin Method (N/A)
- Acute Porphyrias: Biomarkers for Disease Activity and Response to Treatment (N/A)
- Prevention of Post-ERCP Acute Pancreatitis by Heme-oxygenase Activation Through the Administration of Hemin : a Prospective, Randomized Double Blind Controlled Trial (Phase 2)
- A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |